Where does PhaseRx, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), PhaseRx, Inc. ranks #23,191 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does PhaseRx, Inc. hold?

PhaseRx, Inc. holds 12 US utility patents granted between 2015 and 2018, spanning 9 technology areas.

What is PhaseRx, Inc.'s Innovation Score?

PhaseRx, Inc. has an Innovation Score of 30.0 out of 100 (33rd percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does PhaseRx, Inc. focus on?

PhaseRx, Inc.'s top technology area is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes) with 12 patents, ranking #1,877 of 7,163 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is PhaseRx, Inc.'s patent grant rate increasing or decreasing?

PhaseRx, Inc.'s recent grant velocity is -100% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for PhaseRx, Inc.'s patents?

PhaseRx, Inc.'s patents average 17.5 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the PhaseRx, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

PhaseRx, Inc.

USPTO PatentsView assignee record - 12 granted patents across 9 technology areas, recorded in grant years 2015–2018. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61K (Preparations FOR Medical, Dental OR Toiletry Purposes).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Phaserx ranks #23,191 of 49,997 tracked US assignees by granted-patent volume, with 12 patents across 9 technology areas.

#23,191
of 49,997 US assignees by volume: 33rd percentile
by Innovation Score (30.0/100): 17.5
avg claims per patent: -100%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R23191 · US Corporation #23,191 · 12 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 12 grants
MID-PACK #23,191/49,997
PHOTO-FINISH Pernix Sleep
CPC-NARROW A61K · 9 areas
INNOV-THIN 30.0/100
CLAIMS-RICH 17.5 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -100% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Pernix Sleep, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Phaserx’s 30.0 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.9 pts (30%) Velocity 0.0 pts (0%) Breadth 10.6 pts (35%) Claim depth 10.5 pts (35%)

Qualcomm Incorporated · highest

85
PhaseRx · this assignee

30
3D Lighting… · lowest

7

What this shows Phaserx's Innovation Score is 30.0/100 (33rd percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Phaserx?

Each dot is one of Phaserx’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Phaserx’s own 17.5 claims/patent is ABOVE the 11.3 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Phaserx vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Phaserx's grants concentrate

PhaseRx, Inc. is a focused PatentsView assignee: 9 CPC subclasses with 100% of grants classified under A61K (Preparations FOR Medical, Dental OR Toiletry Purposes). Peak complete grant year is 2016 (4 grants) versus a trough of 2 in 2017. By volume, Phaserx sits between Pernix Sleep, Inc. and Picote Solutions Oy Ltd.

Pernix Sleep

12
Petram

12
Pharmaceutical Pr…

12
Phase 5 Weapon Sy…

12
Phillips Connect

12
Philo

12
Picobrew

12
Picote Solutions…

12
Phaserx ◀

12

What this shows PhaseRx holds 12 patents at rank #23,205, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near PhaseRx

By rank, the assignees closest to #23,205 in granted patent volume.

Leaders in A61K (Preparations FOR Medical)

Other assignees with the most granted patents in PhaseRx's primary technology class.

Phaserx's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

30 33rd percentile higher than 33% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2018

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

PhaseRx, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	3	25.0%
2016	4	33.3%
2017	2	16.7%
2018	3	25.0%

Which technologies does PhaseRx, Inc. patent most?

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 12

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 10

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 9

C08F - Macromolecular Compounds Obtained BY Reactions Only Involving Carbon-to-carbon Unsaturated Bonds 9

C07K - Peptides 3

Y02A - Technologies FOR Adaptation TO Climate Change 3

C08L - Compositions OF Macromolecular Compounds 1

C12Y - Enzymes 1

A01K - Animal HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; Rearing OR Breeding Animals, NOT Otherwise Provided FOR; NEW Breeds OF Animals 1

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

PhaseRx, Inc.'s patent record in context - here's where to go next.

PhaseRx, Inc.'s lead technology class is A61K (Preparations FOR Medical, Dental OR Toiletry Purposes), 100% of its portfolio - see every assignee active in that class. Explore A61K
Ranked #23,191 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare PhaseRx, Inc. against Pernix Sleep, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 30.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.